Abatacept

證據等級: L5

預測適應症: 10 個

ABATACEPT: Drug Repurposing Evaluation Report

One-Sentence Summary

Abatacept (DrugBank: DB01281) is a biologic agent known internationally for immune modulation, but it currently has no marketing authorization in Taiwan and no original indication data in this evidence pack. The TxGNN model has not generated any predicted new indications for this drug, and critical data gaps remain in mechanism of action and safety information.

Quick Overview

Item	Content
Drug Name (INN)	ABATACEPT
DrugBank ID	DB01281
Original Indication	No data available (no Taiwan licenses)
Predicted New Indication	None (no TxGNN predictions)
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model prediction only; no predictions generated
Taiwan Market Status	✗ Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Abatacept is widely recognized internationally as a selective T-cell co-stimulation modulator (CTLA-4-Ig fusion protein) that inhibits T-cell activation by binding to CD80/CD86 on antigen-presenting cells. It is approved in many countries for rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis; however, none of this information is captured in the current Taiwan regulatory dataset.

Since the TxGNN model has not generated any predicted indications for Abatacept, there is no mechanistic bridging analysis to perform at this time. The absence of predictions may be due to insufficient representation of Abatacept in the knowledge graph, or it may indicate that the model did not identify high-confidence repurposing candidates above its scoring threshold.

Clinical Trial Evidence

Currently no related clinical trials to report, as no new indications have been predicted by the TxGNN model.

Literature Evidence

Currently no related literature to report, as no new indications have been predicted by the TxGNN model.

Taiwan Market Information

Abatacept currently holds no marketing authorization (許可證) in Taiwan. No license records were returned from the TFDA query (queried 2026-03-29).

Safety Considerations

Please refer to the package insert for safety information.

All safety fields (key warnings, contraindications, drug-drug interactions) returned as data gaps in this evidence pack. The DDI query returned no results. Complete safety data should be obtained from international sources (e.g., FDA label, EMA SmPC) or the DrugBank full profile before any clinical evaluation proceeds.

Data Gaps Summary

The following critical data gaps were identified and must be resolved before advancing this candidate:

Gap ID	Category	Item	Severity	Remediation
DG001	Drug Level	TFDA Package Insert Warnings/Contraindications	Blocking	Download and parse package insert PDF from TFDA website
DG002	Drug Level	Mechanism of Action (MOA)	High	Query DrugBank API for detailed MOA

Conclusion and Next Steps

Decision: Hold

Rationale: Abatacept has no TxGNN-predicted new indications in the current analysis, no Taiwan marketing authorization, and multiple blocking data gaps. There is insufficient evidence to justify advancing this candidate through the repurposing pipeline at this time.

To proceed, the following is needed:

Resolve DG001 (Blocking): Obtain TFDA package insert warnings and contraindications, or equivalent safety data from international regulatory sources (FDA/EMA)
Resolve DG002 (High): Retrieve detailed mechanism of action from DrugBank API to enable knowledge graph enrichment
Re-run TxGNN prediction after knowledge graph is updated with complete Abatacept pharmacological data
If international indications (e.g., rheumatoid arthritis, JIA, psoriatic arthritis) are confirmed, populate original_indications and re-evaluate for repurposing opportunities
Confirm whether Abatacept's absence from the Taiwan market is a regulatory gap or a strategic decision, as this affects the feasibility of any repurposing pathway in Taiwan
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.